BLUJEPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLUJEPA (BLUJEPA).
BLUJEPA (belzutifan) is a hypoxia-inducible factor-2α (HIF-2α) inhibitor. It binds to HIF-2α, preventing its heterodimerization with HIF-1β and subsequent transcription of genes involved in proliferation, angiogenesis, and metabolism.
| Metabolism | Primarily metabolized by CYP2C9 and CYP3A4; minor contributions from CYP2C19. |
| Excretion | Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine and feces. |
| Half-life | Terminal elimination half-life is approximately 50 hours (range 40-60 h), supporting once-daily dosing. |
| Protein binding | 97-99% bound primarily to serum albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 5-10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 30-60% (dose-dependent, with high-fat meal increasing exposure ~2-fold). |
| Onset of Action | Oral: Time to peak effect (e.g., reduction in mutant IDH1 levels) is 4-8 hours post-dose. |
| Duration of Action | Clinical effect duration corresponds to dosing interval (24 h) with sustained inhibition of 2-hydroxyglutarate production. |
400 mg orally twice daily with or without food.
| Dosage form | TABLET |
| Renal impairment | CrCl ≥30 mL/min: no adjustment; CrCl <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 300 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established in pediatric patients. |
| Geriatric use | No dose adjustment required; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BLUJEPA (BLUJEPA).
| Breastfeeding | No human data. Animal studies indicate drug and/or metabolites excreted in milk. M/P ratio unknown. Advise not to breastfeed during treatment and for 1 week after last dose due to potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | BLUJEPA is contraindicated in pregnancy. First trimester: high risk of teratogenicity based on animal studies showing embryolethality and malformations. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Use effective contraception during treatment and for 1 month after final dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
None.
| Precautions | Anemia (may require transfusion), hypoxia, embryofetal toxicity (teratogenicity based on mechanism, including risk of fetal loss), and reversible posterior leukoencephalopathy syndrome (PRES) have been reported. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. No other known food interactions. |
| Clinical Pearls | BLUJEPA (peficitinib) is a Janus kinase (JAK) inhibitor primarily used for rheumatoid arthritis. Monitor for serious infections, including tuberculosis, hepatitis B reactivation, and herpes zoster. Perform baseline and periodic lipid monitoring. Contraindicated in patients with severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors; reduce dose if concomitant use unavoidable. |
Loading safety data…
| Fetal Monitoring |
| Pregnancy test before initiation and monthly during treatment. Monitor for fetal growth via ultrasound if pregnant. Assess for signs of premature labor or placental insufficiency. Maternal monitoring includes liver function tests and blood pressure. |
| Fertility Effects | May impair male and female fertility. Animal studies show reduced spermatogenesis and ovarian follicle depletion. Reversibility unknown. Advise fertility preservation options (e.g., sperm or egg banking) prior to treatment. |
| Patient Advice | Take the medication exactly as prescribed; do not change dose or stop without consulting your doctor. · Report any signs of infection (fever, chills, cough, pain on urination) promptly. · Avoid live vaccines during treatment and for at least 2 months after stopping. · Inform your doctor if you have a history of hepatitis, tuberculosis, or blood clots. · Do not take this medication if you are pregnant, planning to become pregnant, or breastfeeding. |